Anticoagulation Medical Home

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

162 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-10-21

Study Completion Date

2018-01-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary study goal is to improve the quality of care transitions for patients with new episodes of venous thromboembolism (VTE).

Primary Outcomes: To measure differences in the quality of care transition, as measured by the Care Transition Measure (CTM)-15 in the investigators target population of patients with incident VTE randomized to either a multicomponent, anticoagulation medical home intervention or usual care.

Secondary Major Outcomes: To measure the difference in recurrent VTE, major hemorrhage, all-cause re-admissions, and mortality between the investigators intervention and comparison groups at 30 and 90 days in the investigators target population.

Secondary Other Outcomes: To measure patient knowledge, health-related quality of life, and time in the therapeutic range (TTR) for patients on warfarin in the investigators target population.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Venous Thromboembolism (VTE) Prophylaxis in Medically Ill Patients

NCT00810784

Venous Thromboembolism

COMPLETED

Risk Factors for Venous Thromboembolism in the Community

NCT00011180

Cardiovascular Diseases Thromboembolism

COMPLETED

Epidemiology of Venous Thromboembolism

NCT00041457

Cardiovascular Diseases Thromboembolism Peripheral Vascular Diseases

COMPLETED

VTE Prophylaxis Guidelines in Hospitalized Elders

NCT03025100

Venous Thromboembolism

COMPLETED

Implementing VTE Prevention in Ambulatory Cancer Care

NCT07292376

Venous Thromboembolism Neoplasms

ENROLLING_BY_INVITATION NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Venous Thromboembolism Patient-Centered Care

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control

The control group will receive usual care; no interventions will be administered.

Group Type NO_INTERVENTION

No interventions assigned to this group

Intervention

Interventions will be administered to this group. Patients in the Intervention Group will: 1) have an in-home pharmacist medication assessment; 2) receive enhanced medication instructions (including pictograms); 3) receive an additional individualized assessment and educational session with a clinician provider related to the medication management for their disease (VTE).

Group Type EXPERIMENTAL

Enhanced Assessment and Education

Intervention Type BEHAVIORAL

Patients in the Intervention Group will: 1) have an in-home pharmacist medication assessment; 2) receive enhanced medication instructions (including pictograms); 3) receive an additional individualized assessment and educational session with a clinician provider related to the medication management for their disease (VTE).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Enhanced Assessment and Education

Patients in the Intervention Group will: 1) have an in-home pharmacist medication assessment; 2) receive enhanced medication instructions (including pictograms); 3) receive an additional individualized assessment and educational session with a clinician provider related to the medication management for their disease (VTE).

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* hospital admission;
* diagnosis of:

* VTE (first or subsequent episode); or
* DVT of leg or pelvis or upper extremities or other site confirmed by ultrasound or CT scan; or
* PE with a positive CT spiral exam, pulmonary arteriogram, CT angiogram, or high probability ventilation perfusion scan.
* for whom it is anticipated the treating medical team will prescribe an oral anticoagulant upon hospital discharge.